HEXO Strengthens Commitment to Research and Innovation, Appointing Chief Innovation Officer
15 January 2019 - 10:30PM
HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO) is
strengthening its commitment towards research and innovation
by appointing Veronique Hamel as its Chief Innovation
Officer. With global experience in new product development Ms.
Hamel is well positioned to develop research strategy and
oversee HEXO Corp’s research and innovation pipeline.
“I am pleased to welcome Veronique to our
leadership team,” said HEXO’s CEO and co-founder, Sebastien
St-Louis. “Veronique has a track record for building and helping
shape high growth and consumer-centric organizations through
trusted and award-winning innovations. She brings a strong business
acumen to the process of innovation as well as a passion for
break-throughs and industry firsts.”
Throughout her career spanning over 25
years, Veronique Hamel has developed expertise in
innovation through leadership roles in research and
development, new product
development, marketing, and business development for global consumer goods
and pharmaceutical
companies in Europe, the U.S. and
Canada.
Most recently, Veronique has built strong, innovative teams
in Canada at Church & Dwight Canada,
Bausch & Lomb and Bausch
Health Companies Inc.
“I am proud to join the competent team
at HEXO,” said Veronique Hamel. “HEXO has already shown
extraordinary commitment to quality and innovation and
has been recognized for that. I am thrilled to be on board to
expand the Company’s innovation footprint and bring exciting, new
and trusted solutions to consumers.”
Veronique Hamel is a graduate from EDHEC Business school in
France.
About HEXO Corp. HEXO Corp creates and
distributes award-winning, innovative, easy-to-use products to
serve the Canadian cannabis market. One of the country’s
lowest-cost producers, HEXO currently operates with over 310,000
sq. ft. of production capacity with construction on another
1,000,000 sq. ft. expansion set to be complete by year
end. HEXO serves the adult-use market under the HEXO brand,
while continuing to serve its medical cannabis clients through the
well-known Hydropothecary brand. For more
information please visit hexocorp.com.
Forward-Looking Information This press
release may contain forward-looking information that is based on
certain assumptions and involves known and unknown risks and
uncertainties and other factors that could cause actual events to
differ materially from current assumptions and expectations. These
statements should not be read as guarantees of future performance
or results. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements. A more complete discussion of the risks
and uncertainties facing the Company appears in the Company’s
Annual Information Form and continuous disclosure filings, which
are available on SEDAR’s website at www.sedar.com. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
The Company disclaims any intention or obligation, except to the
extent required by law, to update or revise any forward-looking
statements as a result of new information or future events, or for
any other reason. Neither the Toronto Stock
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Investor Relations: Kathy
Chow 1-866-438-8429 invest@HEXO.com www.hexocorp.com
Media Relations: Sarah Brown (819)
317-0526 media@hexo.com Director Adam
Miron 819-639-5498
A photo accompanying this announcement is available
at: http://www.globenewswire.com/NewsRoom/AttachmentNg/0492e712-53e6-4025-bbfe-b8862b8b0c92
HEXO (TSX:HEXO)
Historical Stock Chart
From Apr 2024 to May 2024
HEXO (TSX:HEXO)
Historical Stock Chart
From May 2023 to May 2024